Byondis
Anja Scholzen is a highly experienced Senior Scientist specializing in biomarker development in immunology. Currently at Byondis since June 2021, Anja oversees biomarker strategies for immuno-oncology projects and manages assay development and validation for first-in-human trials. Previously at Innatoss Laboratories from July 2016 to June 2021, Anja served as the principal investigator on US Defense Threat Reduction Agency-funded projects and contributed to Horizon2020 initiatives, publishing eight peer-reviewed papers. Anja's academic background includes a postdoctoral researcher position at Radboud University Nijmegen Medical Centre, focused on malaria immunology, as well as research roles at Monash University and the University of Melbourne, culminating in a PhD in Immunology. Anja has also engaged in journalism and publishing prior to a dedicated career in scientific research.
This person is not in the org chart
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.